本文選題：乳腺癌 + 卵巢癌��； 參考：《山東醫(yī)藥》2017年35期

【摘要】：目的探討乳腺癌、卵巢癌組織NPR1基因表達(dá)變化與乳腺癌、卵巢癌預(yù)后的關(guān)系。方法用Oncomine數(shù)據(jù)庫分析乳腺癌組織、卵巢癌組織和正常組織中NPR1基因表達(dá)的差異,用Kaplan-Meier Plotter數(shù)據(jù)庫進(jìn)行乳腺癌、卵巢癌患者生存分析,分析乳腺癌、卵巢癌組織NPR1基因表達(dá)變化與乳腺癌、卵巢癌預(yù)后的關(guān)系。結(jié)果 Oncomine數(shù)據(jù)庫包含了715個(gè)數(shù)據(jù)集和86 733個(gè)樣本。大數(shù)據(jù)分析結(jié)果顯示正常乳腺組織中NPR1基因高表達(dá),乳腺癌組織中NPR1基因低表達(dá)。正常卵巢組織中NPR1基因低表達(dá),卵巢癌組織中NPR1基因高表達(dá)。KaplanMeier Plotter數(shù)據(jù)庫包含了54 675個(gè)基因和10 461個(gè)癌癥樣本信息,其中包含5 143個(gè)乳腺癌患者樣本,1 861個(gè)卵巢癌患者樣本。大數(shù)據(jù)分析結(jié)果顯示乳腺癌組織NPR1基因高表達(dá)的患者無病生存時(shí)間較長(P0.05)�；讟有腿橄侔�、腺腔B型乳腺癌和HER2過表達(dá)型乳腺癌NPR1基因低表達(dá)和高表達(dá)患者預(yù)后無明顯差異(P均0.05);腺腔A型乳腺癌患者NPR1高表達(dá)預(yù)后明顯好于低表達(dá)者(P0.05)。卵巢癌組織NPR1基因低表達(dá)者的無進(jìn)展生存時(shí)間比高表達(dá)者長(P0.05)。具體細(xì)分,漿液性卵巢癌和子宮內(nèi)膜性卵巢癌組織NPR1基因低表達(dá)者的預(yù)后明顯好于高表達(dá)者(P均0.05)。結(jié)論乳腺癌組織NPR1基因高表達(dá)提示預(yù)后良好,而卵巢癌組織NPR1基因高表達(dá)提示預(yù)后不良。
[Abstract]:Objective to investigate the relationship between the expression of NPR1 gene and prognosis of breast cancer and ovarian cancer. Methods Oncomine database was used to analyze the difference of NPR1 gene expression in breast cancer, ovarian cancer and normal tissues. Kaplan-Meier Plotter database was used to analyze the survival of patients with breast cancer and ovarian cancer. Relationship between expression of NPR1 gene and prognosis of breast cancer and ovarian cancer. Results the Oncomine database contained 715 data sets and 86,733 samples. Big data analysis showed that NPR1 gene was highly expressed in normal breast tissue and NPR1 gene was low in breast cancer tissue. The overexpression of NPR1 gene in normal ovarian tissues. Kaplan Meier Plotter database contained 54 675 genes and 10 461 cancer samples, including 5 143 breast cancer samples and 1 861 ovarian cancer samples. Big data analysis showed that patients with high expression of NPR1 gene had a longer disease-free survival time (P 0.05). There was no significant difference in the prognosis of patients with low expression and high expression of NPR1 gene in basal type B breast cancer and HER2 overexpression type B breast cancer (P 0.05), and the prognosis of NPR1 high expression in type A breast cancer was significantly better than that in low expression group (P 0.05). The progression-free survival time of patients with low expression of NPR1 gene was longer than that of patients with high expression of NPR1 gene. The prognosis of patients with low expression of NPR1 gene in serous ovarian cancer and endometrial ovarian carcinoma was significantly better than that in those with high expression (P 0.05). Conclusion the high expression of NPR1 gene in breast cancer may indicate a good prognosis, while the high expression of NPR1 gene in ovarian cancer may suggest a poor prognosis.
【作者單位】： 中國醫(yī)科大學(xué)藥學(xué)院藥理教研室遼寧省分子靶向抗腫瘤藥物藥理學(xué)研究與評價(jià)重點(diǎn)實(shí)驗(yàn)室;
【基金】：遼寧省高校創(chuàng)新團(tuán)隊(duì)計(jì)劃資助項(xiàng)目(LT2014016) 遼寧省科技計(jì)劃項(xiàng)目(2014226033) 遼寧省高等學(xué)校優(yōu)秀人才支持計(jì)劃項(xiàng)目(LJQ2015118) 沈陽市科技計(jì)劃項(xiàng)目(F16-094-1-00);沈陽市科技計(jì)劃項(xiàng)目(17-123-9-00)
【分類號(hào)】：R737.31;R737.9
，

本文編號(hào)：1799307